Honasa Consumer Calls Off Proposed Acquisition of Fluence Pharma

NEW DELHI — Honasa Consumer Limited, the parent company of popular personal care brands including Mamaearth, officially called off its proposed acquisition of a 58% equity stake in Fluence Pharma Private Limited on August 25, 2026. The FMCG major notified the National Stock Exchange of India (NSE) and BSE Limited that the transaction was terminated at 9:20 AM IST due to the non-fulfillment of mandatory closing conditions outlined under the Share Purchase Agreement (SPA). The cancellation halts a transaction originally approved by Honasa’s board in June 2026 that valued Fluence Pharma at an enterprise value of ₹135 crore.

Share Purchase Agreement Terminated Due to Unmet Conditions

According to an official regulatory filing submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Honasa Consumer Limited confirmed the complete termination of the deal. The initial proposal, announced on June 23, 2026, aimed to give Honasa controlling ownership of Fluence Pharma subject to standard precedent conditions.

However, because key closing conditions specified in the executed Share Purchase Agreement were not met within the stipulated timeline, the board decided to withdraw from the acquisition. Honasa did not disclose the precise commercial or legal terms that remained unfulfilled prior to the deal's termination.

Context of the Fluence Pharma Deal and Strategy

The proposed transaction was intended to mark Honasa Consumer’s strategic entry into the fast-growing ₹16,000 crore+ Indian nutraceuticals market. Fluence Pharma Private Limited, founded by CEO Amit Bhusari and dermatologist Dr. Rajendra Singh Rajput, specializes in condition-specific over-the-counter (OTC) supplements using its patented Cyclical Nutrition Therapy (CNT) model.

Fluence Pharma reported provisional revenues of approximately ₹40 crore for FY26 with an operating EBITDA margin exceeding 20%. Over 70% of its revenue was generated from hair-care supplements distributed across a medical network of more than 3,000 dermatologists. Honasa had previously outlined plans to leverage Fluence’s clinical R&D to build a dedicated ₹500 crore B2C nutraceuticals unit under its subsidiary, Honasa Health Private Limited.

Market Impact and Outlook for Investors

The cancellation of the ₹135 crore enterprise deal impacts short-term growth models for Honasa's newly established health and wellness division. However, the company assured shareholders that its broader capital deployment strategies remain intact.

• Investors & Shareholders: The termination protects Honasa's cash balance sheet from inorganic acquisition outlay, leaving capital available for organic execution or alternative M&A.

• Nutraceutical Market Operations: Honasa confirmed it will continue to evaluate both organic and inorganic opportunities to expand its footprint in the "beauty-from-inside" supplement category.

• Retail Consumers & Brands: Distribution of existing Honasa personal care products under brands such as Mamaearth, The Derma Co., and Aqualogica will remain entirely unaffected by the regulatory withdrawal.

Official Sources Section

Information regarding the cancellation was disclosed by Honasa Consumer Limited in a formal regulatory filing sent to Indian stock exchanges.

According to official announcements made to the National Stock Exchange of India and BSE Limited, Company Secretary and Compliance Officer Gaurav Pandit confirmed that the proposed acquisition of Fluence Pharma Private Limited was called off at 9:20 AM IST on August 25, 2026. Additional strategic details were referenced from previous corporate filings made to the Securities and Exchange Board of India.

Quote Section

According to officials at Honasa Consumer Limited, "The Company has today, August 25, 2026, called off the proposed acquisition of Fluence Pharma due to non-fulfilment of closing conditions specified under the Share Purchase Agreement. The Company remains committed to its Nutraceutical strategy and will continue to evaluate the right opportunities, organic and inorganic, to build a strong consumer-focused business in this category."

Why It Matters

The cancellation highlights strict corporate governance and compliance discipline among publicly traded D2C and FMCG conglomerates in India. By refusing to waive precedent conditions, Honasa avoids potential integration risks or financial exposure. While this temporarily delays Honasa's inorganic expansion into prescription-led dermatological supplements, it underscores a cautious corporate approach toward high-value M&A transactions.

Key Facts at a Glance

• Transaction: Acquisition of a 58% controlling stake in Fluence Pharma Private Limited called off.

• Deal Valuation: Valued at an enterprise valuation of ₹135 crore when announced on June 23, 2026.

• Reason for Withdrawal: Non-fulfillment of mandatory closing conditions under the Share Purchase Agreement.

• Future Roadmap: Honasa maintains its broader strategy to build a consumer-focused nutraceuticals business organically or through new acquisitions.

Frequently Asked Questions (FAQ)

Why did Honasa Consumer call off the Fluence Pharma acquisition?

Honasa Consumer terminated the proposed deal because certain prerequisite conditions outlined in the Share Purchase Agreement were not fulfilled by the specified closing timeline.

How much was the Fluence Pharma deal valued at?

When the acquisition of the 58% stake was initially approved in June 2026, Fluence Pharma was valued at an enterprise value of ₹135 crore.

What does Fluence Pharma specialize in?

Fluence Pharma is a nutraceutical firm that develops scientific OTC supplements for skin and hair health using a proprietary mechanism known as Cyclical Nutrition Therapy (CNT).

Will Honasa Consumer stop its plan to enter the nutraceutical market?

No. Honasa officially stated that it remains fully committed to its nutraceutical strategy and will continue exploring organic product development alongside alternative inorganic acquisition opportunities.

Source: Official regulatory disclosures submitted to the National Stock Exchange of India, BSE Limited, and Honasa Consumer Limited Investor Relations.